Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C DeConti

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Connecticut Medicine|April 1, 1971
Correctable complications of neoplastic disease. I. HypercalcemiaR C DeConti
JAMA|February 8, 1971
Procarbazine in the management of late Hodgkin's diseaseR C DeConti
Annals of Internal Medicine|October 1, 1970
Calabresi P: Treatment of polycythemia vera with azauridine and azaribineR C Deconti
Cancer|September 1, 1981
A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancerR C DeConti, D Schoenfeld
Cancer|October 1, 1970
Immunosuppression by 5-fluorouracilM S Mitchell, R C DeConti
Blood|May 1, 1972
Endotoxin stimulation in patients with lymphoma: correlation with the myelosuppressive effects of alkylating agentsR C DeConti, S R Kaplan, P Calabresi
Cancer Chemotherapy Reports|November 1, 1975
Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumorsO O Odujinrin, R C DeConti, J R Bertino
The Annals of Otology, Rhinology, and Laryngology|June 1, 1989
Growth and chemosensitivity of human head and neck cancers implanted under the kidney capsule of cyclosporine-immunosuppressed miceJ A Bennett, S M Parnes, R C DeConti
Cancer Chemotherapy Reports|June 1, 1970
Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065)W A Creasey, R L Capizzi, R C DeConti
Cancer Chemotherapy Reports|December 1, 1971
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962)J C Marsh, R C DeConti, S P Hubbard
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Connecticut Medicine|April 1, 1971
Correctable complications of neoplastic disease. I. HypercalcemiaR C DeConti
JAMA|February 8, 1971
Procarbazine in the management of late Hodgkin's diseaseR C DeConti
Annals of Internal Medicine|October 1, 1970
Calabresi P: Treatment of polycythemia vera with azauridine and azaribineR C Deconti
Cancer|September 1, 1981
A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancerR C DeConti, D Schoenfeld
Cancer|October 1, 1970
Immunosuppression by 5-fluorouracilM S Mitchell, R C DeConti
Blood|May 1, 1972
Endotoxin stimulation in patients with lymphoma: correlation with the myelosuppressive effects of alkylating agentsR C DeConti, S R Kaplan, P Calabresi
Cancer Chemotherapy Reports|November 1, 1975
Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumorsO O Odujinrin, R C DeConti, J R Bertino
The Annals of Otology, Rhinology, and Laryngology|June 1, 1989
Growth and chemosensitivity of human head and neck cancers implanted under the kidney capsule of cyclosporine-immunosuppressed miceJ A Bennett, S M Parnes, R C DeConti
Cancer Chemotherapy Reports|June 1, 1970
Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065)W A Creasey, R L Capizzi, R C DeConti
Cancer Chemotherapy Reports|December 1, 1971
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962)J C Marsh, R C DeConti, S P Hubbard
Pageof 5